Zinc

Overview

A metallic element of atomic number 30 and atomic weight 65.38. It is a necessary trace element in the diet, forming an essential part of many enzymes, and playing an important role in protein synthesis and in cell division. Zinc deficiency is associated with anemia, short stature, hypogonadism, impaired wound healing, and geophagia. It is identified by the symbol Zn . A newer study suggests implies that an imbalance of zinc is associated with the neuronal damage associated with traumatic brain injury, stroke, and seizures . Understanding the mechanisms that control brain zinc homeostasis is, therefore, imperative to the development of preventive and treatment regimens for these and other neurological disorders . In addition to the above, recent review articles have already demonstrated the important role of zinc in the pathophysiology and treatment of affective disorders, plus discussed the potential value of zinc as a marker of these diseases . Most recently, research has shown that polymorphism of the common polymorphism in zinc transporter SLC30A8/ZnT8 may increase susceptibility to type 2 diabetes provided novel insights into the role of zinc in diabetes .

Indication

Zinc can be used for the treatment and prevention of zinc deficiency/its consequences, including stunted growth and acute diarrhea in children, and slowed wound healing. It is also utilized for boosting the immune system, treating the common cold and recurrent ear infections, as well as preventing lower respiratory tract infections .

Associated Conditions

Candidiasis
Common Cold
Diaper Dermatitis
Diaper Rash
Eye redness
Iron Deficiency (ID)
Ocular Irritation
Skin Irritation
Sunburn
Wilson's Disease
Zinc Deficiency

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Effect of Zinc Supplementation on Hyperhomocysteinemia Compared to Folic Acid in CKD Patient on Hemodialysis	2025/02/26	NCT06847139	Not Applicable	Recruiting	Chittagong Medical College
Impact of Zinc As a New Adjuvant Therapy for Cow Milk Protein Allergy in Children.	2024/11/04	NCT06673082	Not Applicable	ENROLLING_BY_INVITATION	Kasr El Aini Hospital
The Effect of Probiotic and Zinc Supplementation in Patients With Gastroesophageal Reflux Disease	2024/10/29	NCT06664008	Phase 4	Not yet recruiting	Ain Shams University
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis	2024/08/23	NCT06567717	Phase 2	Not yet recruiting	Cedars-Sinai Medical Center
Comparison of Effectiveness of Zinc Supplementation With ORS and Bacillus Clausii Versus Zinc With ORS and Saccharomyces Boulardii in Acute Watery Diarrhea in Paediatric Patients	2024/08/06	NCT06540209	Not Applicable	Completed	RESnTEC, Institute of Research
The Clinical Investigation of Colgate Dual Zinc Toothpaste as Compared to Colgate Cavity Protection Toothpaste in Controlling Established Plaque and Gingivitis	2024/05/28	NCT06430060	Phase 3	Not yet recruiting	Colgate Palmolive
Efficacy and Safety of 30% Supramolecular Salicylic Acid Combined With Supramolecular Active Zinc in the Treatment of Malassezia Folliculitis	2024/03/12	NCT06307223	Phase 4	Completed	Second Affiliated Hospital of Xi'an Jiaotong University
The Effect of Platelet-rich Plasma Nasal Injection in the Treatment of Traumatic Olfactory Dysfunction	2024/03/04	NCT06290219	Phase 3	Not yet recruiting	Taichung Veterans General Hospital
Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial	2024/02/15	NCT06260891	Phase 2	Not yet recruiting	University of California, San Francisco
Effect of Probiotic and Zinc Supplementations on the Clinical Outcome in Pediatric Patients with Ventriculitis	2023/11/30	NCT06151392	Phase 4	Recruiting	Ain Shams University

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
Immu-n Waker	Newton Laboratories, Inc.	55714-2596	ORAL	15 [hp_X] in 1 mL	5/21/2025
Niferex	Avion Pharmaceuticals, LLC	75854-344	ORAL	15 mg in 1 1	4/8/2025
Chromagen	Avion Pharmaceuticals, LLC	75854-320	ORAL	12 mg in 1 1	1/18/2021
Immu-n Waker	Newton Laboratories, Inc.	55714-4862	ORAL	15 [hp_X] in 1 mL	5/21/2025
12 Male Reproductive	The Wellness Center	50181-0030	ORAL	1 [hp_M] in 1 mL	5/28/2025
VACC HC	Deseret Biologicals, Inc.	43742-2218	ORAL	30 [hp_X] in 1 mL	5/27/2025
Back, Muscle and Joint Relief	King Bio Inc.	57955-2822	ORAL	10 [hp_X] in 59 mL	5/20/2025
Vitmin C	Dr. Masood Homeopathic Pharmaceuticals Private Limited	82797-132	ORAL	0.01 mg in 120 mL	4/24/2025
M-Natal Plus	METHOD PHARMACEUTICALS, LLC	58657-170	ORAL	25 mg in 1 1	12/10/2023
Vitafol Plus	Everett Laboratories, Inc.	0642-0092	ORAL	15 mg in 1 1	4/18/2012

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
Wilzin	Recordati Rare Diseases,Immeuble le Wilson,70, avenue du Général de Gaulle,92800 Puteaux,France	Authorised	10/12/2004

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
BRAUER CALM Oral Spray	65600	Brauer Natural Medicine Pty Ltd	Medicine	A	7/31/1998
Restless Legs Relief	169216	Martin & Pleasance Pty Ltd	Medicine	A	2/18/2010
Hair Assist Women's Foam	400972	DPP Pharmaceuticals Pty Ltd	Medicine	A	12/12/2022
Calm Oral Liquid	492207	Brauer Natural Medicine Pty Ltd	Medicine	A	6/19/2025
Calm Oral Liquid	455427	Brauer Natural Medicine Pty Ltd	Medicine	A	7/16/2024
HAIR ASSIST	115642	DPP Pharmaceuticals Pty Ltd	Medicine	A	1/14/2005
Calm Oral Liquid	345751	Brauer Natural Medicine Pty Ltd	Medicine	A	10/12/2020
Hair Assist Men's Foam	400970	DPP Pharmaceuticals Pty Ltd	Medicine	A	12/12/2022
BRAUER CALM TABLETS	65601	Brauer Natural Medicine Pty Ltd	Medicine	A	7/31/1998
DANMOT HERBALIX CHELATION FORMULA tablet bulk	52268	Danmot Pty Ltd	Medicine	A	4/18/1995

Related News

Implantable Biobattery Achieves 99.6% Tumor Reduction in Breakthrough Drug-Free Cancer Treatment

a month ago

A novel implantable biobattery developed by researchers at University of Wollongong and Jilin University reduced tumor size from over 1,000 mm³ to just 4 mm³ in 14 days, achieving a 99.6% reduction.

Mangoceuticals Advances H1N1 Study and Expands Research to H5N1 Influenza

5 months ago

• Mangoceuticals reports promising progress in H1N1 efficacy study, demonstrating significant viral load reduction through their proprietary polyphenol and zinc formulation. • The company is expanding its research to include H5N1 (avian influenza) testing, running concurrent studies at Vipragen Biosciences' AAALAC-accredited facility in Mysuru, India. • The advancement represents a strategic expansion of Mangoceuticals' respiratory illness prevention platform, addressing multiple viral threats through innovative technology.

Open Philanthropy Awards $1.5 Million to Cures Within Reach for Repurposing Research in LMICs

7 months ago

• Cures Within Reach (CWR) receives $1.5 million from Open Philanthropy to support clinical trials in low- and middle-income countries (LMICs). • The funding will support CWR's ReGRoW initiative, which focuses on repurposing readily available generic medicines and indigenous treatments. • CWR's approach allows researchers in LMICs to set their own priorities, addressing specific health challenges in their communities. • Previous CWR-funded trials, like the unithiol study for snakebites in Kenya, have demonstrated the value of repurposing existing drugs.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access